Increasing access to HIV prevention therapies in Central Asia
Expanding Medication Assisted Therapies in Central Asia
This study is looking at how to better help people in Central Asia who inject drugs and their partners by making it easier for them to access treatments that can prevent HIV, like combining opioid therapies with HIV medications, and it aims to find out what obstacles are in the way so that healthcare can be improved for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10893503 on NIH RePORTER |
What this research studies
This research focuses on addressing the growing HIV epidemic in Central Asia, particularly among people who inject drugs and their partners. It aims to expand the use of opioid agonist therapies (OAT) and combine them with antiretroviral therapy (ART) to effectively prevent new HIV infections. The study will assess barriers to implementing these therapies in Kazakhstan, Kyrgyzstan, and Tajikistan, using a structured approach to improve healthcare delivery and patient outcomes. By identifying and overcoming challenges, the research seeks to enhance the availability and effectiveness of these critical treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in Central Asia who are at risk of HIV infection, particularly those who inject drugs and their sexual partners.
Not a fit: Patients who are not at risk of HIV infection or do not reside in Central Asia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce new HIV infections and improve the health outcomes of individuals at risk in Central Asia.
How similar studies have performed: Previous research has shown success in scaling up opioid agonist therapies in other regions, indicating that this approach could be effective in Central Asia as well.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Altice, Frederick Lewis — Yale University
- Study coordinator: Altice, Frederick Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.